DocWire News Editors

DocwireNews

The beta-blocker carvedilol showed some benefit for protecting against heart injury resulting from chemotherapy-induced heart damage, but did not protect against heart dysfunction, results from a new study presented at ACC.18 in Orlando suggested.    
The study, which included 200 patients with breast cancer, were randomized to receive either carvedilol at 18.4 mg/day or placebo when beginning anthracycline therapy. The study endpoint was prevention of more than 10% reduction in left ventricular ejection fraction (LVEF) at six months.    
According to the study results, there were no statistically significant differences in the primary study endpoint between the two study groups (14.5% for carvedilol versus 13.5% for placebo). For the secondary study endpoint, there were more patients with elevated levels of troponin I (suggestive of heart damage) in the placebo group than the carvedilol group (41.6% versus 26% respectively). There were no differences in NT-proBNP levels between the groups.    
“Previous studies have shown that higher troponin levels can predict cardiovascular events, and so we could imagine that carvedilol may be able to prevent these events, but we did not see this finding in our study,” lead author Monica Samuel Avila, MD, of the Heart Failure and Heart Transplant Department at Heart Institute, Clinical Hospital of the Medical School of São Paolo, Brazil, said of the results.    
To read more about this study, <a href="http://amcomm.informz.net/z/cjUucD9taT0yMzEwMTk2JnA9MSZ1PTM2OTk2MDI3MCZsaT0xMzk4NDk2OA/index.html">click here</a>.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

CECCY: Carvedilol Shows Mixed Results for Chemotherapy-Induced Damage to Heart

ACC 2018 Conference

The beta-blocker carvedilol showed some benefit for protecting against heart injury resulting from chemotherapy-induced heart damage, but did not protect against heart ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe